Literature DB >> 9836485

Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence.

T Jahkola1, T Toivonen, I Virtanen, K von Smitten, S Nordling, K von Boguslawski, C Haglund, H Nevanlinna, C Blomqvist.   

Abstract

We have recently demonstrated an association between distant metastasis and the expression of the extracellular matrix glycoprotein tenascin-C (Tn-C) in the invasion border of small axillary node-negative breast carcinomas. Our purpose was to assess the relationship between the expression of Tn-C in the tumour invasion border and several histopathological and biological variables and to compare their usefulness in predicting local and distant disease recurrences. The original patient group consisted of 143 women with axillary node-negative breast cancer (one bilateral) treated with breast-conserving surgery and post-operative radiotherapy, and followed for a median of 8 years. Because of the small number of recurrences an additional group of 15 similarly treated women with recurrent breast cancer was also studied. The size of the tumour, its histology, including a possible intraductal component, and grade were re-evaluated. The expression of erbB-2, p53, Ki-67 and Tn-C was evaluated by immunohistochemistry. Ploidy and S-phase fraction (SPF) were assessed by flow cytometry. The only statistically significant prognostic factor for local recurrence was Tn-C expression in the invasion border. For metastasis Ki-67 positivity, tumour size and Tn-C expression in the invasion border were statistically significant, but Ki-67 positivity was the only independent prognostic factor. Tn-C expression in the invasion border was associated with a higher proliferation rate measured by Ki-67 and SPF, which is consistent with the suggested growth-promoting activity of Tn-C. Tn-C may be a useful marker in selecting patients for adjuvant therapies to reduce the rate of both local and distant cancer recurrences.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836485      PMCID: PMC2063217          DOI: 10.1038/bjc.1998.714

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data.

Authors:  B G Haffty; D Fischer; M Rose; M Beinfield; C McKhann
Journal:  J Clin Oncol       Date:  1991-06       Impact factor: 44.544

Review 2.  Tenascin in mammary gland development: from embryogenesis to carcinogenesis.

Authors:  T Sakakura; A Ishihara; R Yatani
Journal:  Cancer Treat Res       Date:  1991

3.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.

Authors:  G M Clark; L G Dressler; M A Owens; G Pounds; T Oldaker; W L McGuire
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

4.  Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy.

Authors:  J Boyages; A Recht; J L Connolly; S J Schnitt; R Gelman; H Kooy; S Love; R T Osteen; B Cady; B Silver
Journal:  Radiother Oncol       Date:  1990-09       Impact factor: 6.280

5.  Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma.

Authors:  J E Ferguson; A M Schor; A Howell; M W Ferguson
Journal:  Differentiation       Date:  1990-02       Impact factor: 3.880

6.  The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast.

Authors:  R Holland; J L Connolly; R Gelman; M Mravunac; J H Hendriks; A L Verbeek; S J Schnitt; B Silver; J Boyages; J R Harris
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

7.  Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast.

Authors:  A A Howeedy; I Virtanen; L Laitinen; N S Gould; G K Koukoulis; V E Gould
Journal:  Lab Invest       Date:  1990-12       Impact factor: 5.662

8.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

9.  Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer.

Authors:  R M Clark; P B McCulloch; M N Levine; M Lipa; R H Wilkinson; L J Mahoney; V R Basrur; B D Nair; R S McDermot; C S Wong
Journal:  J Natl Cancer Inst       Date:  1992-05-06       Impact factor: 13.506

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  47 in total

1.  Breast cancer cell-derived matrix supports vascular morphogenesis.

Authors:  Abigail C Hielscher; Connie Qiu; Sharon Gerecht
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

2.  Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.

Authors:  Keiki Nagaharu; Xinhui Zhang; Toshimichi Yoshida; Daisuke Katoh; Noriko Hanamura; Yuji Kozuka; Tomoko Ogawa; Taizo Shiraishi; Kyoko Imanaka-Yoshida
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Tenascin immunoreactivity in the large bowel and the liver in patients with colorectal cancer.

Authors:  M V Gulubova; T Vlaykova
Journal:  Histochem J       Date:  2001-02

4.  Priming cancer cells for drug resistance: role of the fibroblast niche.

Authors:  Wei Bin Fang; Min Yao; Nikki Cheng
Journal:  Front Biol (Beijing)       Date:  2014-02-01

5.  Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer.

Authors:  Akihiko Takeda; Yoshihide Otani; Hiroyoshi Iseki; Hideki Takeuchi; Kimiyasu Aikawa; Satoru Tabuchi; Nozomi Shinozuka; Toshiaki Saeki; Yasushi Okazaki; Isamu Koyama
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

Review 6.  Bi-directional signaling: extracellular matrix and integrin regulation of breast tumor progression.

Authors:  Scott Gehler; Suzanne M Ponik; Kristin M Riching; Patricia J Keely
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2013       Impact factor: 1.807

7.  Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer.

Authors:  A Brunner; C Mayerl; A Tzankov; I Verdorfer; I Tschörner; H Rogatsch; G Mikuz
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

8.  14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer.

Authors:  Bing Wang; Kang Liu; Hui-Yi Lin; Naresh Bellam; Shiyun Ling; Weei-Chin Lin
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

9.  14-3-3Tau regulates Beclin 1 and is required for autophagy.

Authors:  Bing Wang; Shiyun Ling; Weei-Chin Lin
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

10.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.